{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T04:00:05Z","timestamp":1772078405460,"version":"3.50.1"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T00:00:00Z","timestamp":1612396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"ObsEva SA"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,3,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>STUDY QUESTION<\/jats:title>\n                  <jats:p>Does a single oral dose of nolasiban 900\u2009mg administered 4\u2009h before embryo transfer (ET) increase pregnancy rates in women undergoing IVF?<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>SUMMARY ANSWER<\/jats:title>\n                  <jats:p>In an individual patient data (IPD) meta-analysis of three clinical trials, a single oral dose of nolasiban 900\u2009mg was associated with an increased ongoing pregnancy rate of an absolute 5% (relative 15%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>WHAT IS KNOWN ALREADY<\/jats:title>\n                  <jats:p>Several clinical studies have shown that blocking activation of oxytocin receptors by an oxytocin receptor (OTR) antagonist has the potential to decrease uterine contractions, increase endometrial perfusion and enhance endometrial decidualisation and other parameters of endometrial receptivity. It has been hypothesised that antagonism of oxytocin receptors could improve the likelihood of successful embryo implantation and thus increase pregnancy and live birth rates following ET.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>STUDY DESIGN, SIZE, DURATION<\/jats:title>\n                  <jats:p>This is an analysis of three randomised, double-blind, placebo-controlled trials, which randomised 1836 subjects between 2015 and 2019. We describe the results of a meta-analysis of individual participant data (IPD) from all three trials and the pre-specified analyses of each individual trial.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>PARTICIPANT\/MATERIAL, SETTING, METHODS<\/jats:title>\n                  <jats:p>Participants were patients undergoing ET following IVF\/ICSI in 60 fertility centres in 11 European countries. Study subjects were below 38\u2009years old and had no more than one previously failed cycle. They were randomised to a single oral dose of nolasiban 900\u2009mg (n\u2009=\u2009846) or placebo (n\u2009=\u2009864). In IMPLANT 1, additional participants were also randomised to nolasiban 100\u2009mg (n\u2009=\u200962) or 300\u2009mg (n\u2009=\u200960). Fresh ET of one good quality embryo (except in IMPLANT 1 where transfer of two embryos was allowed) was performed on Day 3 or Day 5 after oocyte retrieval, approximately 4\u2009h after receiving the study treatment. Serum hCG levels were collected at 14\u2009days post oocyte retrieval (Week 2) and for women with a positive hCG result, ultrasound was performed at Week 6 post-ET (clinical pregnancy) and at Week 10 post-ET (ongoing pregnancy). Pregnant patients were followed for maternal (adverse events), obstetric (live birth, gestational age at delivery, type of delivery, incidence of twins) and neonatal (sex, weight, height, head circumference, Apgar scores, congenital anomalies, breast feeding, admission to intensive care and specific morbidities e.g. jaundice, respiratory distress syndrome) outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>MAIN RESULTS AND THE ROLE OF CHANCE<\/jats:title>\n                  <jats:p>In an IPD meta-analysis of the clinical trials, a single oral dose of nolasiban 900\u2009mg was associated with an absolute increase of 5.0% (95% CI 0.5, 9.6) in ongoing pregnancy rate and a corresponding increase of 4.4% (95% CI \u22120.10, 8.93) in live birth rate compared to placebo. Similar magnitude increases were observed for D3 or D5 transfers but were not significantly different from the placebo. Population pharmacokinetics (PK) demonstrated a correlation between higher exposures and pregnancy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>LIMITATIONS, REASON FOR CAUTION<\/jats:title>\n                  <jats:p>The meta-analysis was not a pre-specified analysis. While the individual trials did not show a consistent significant effect, they were not powered based on an absolute increase of 5% in ongoing pregnancy rate. Only a single dose of up to 900\u2009mg nolasiban was administered in the clinical trials; higher doses or extended regimens have not been tested. Only fresh ET has been assessed in the clinical trials to date.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>WIDER IMPLICATIONS OF THE FINDINGS<\/jats:title>\n                  <jats:p>The finding support the hypothesis that oxytocin receptor antagonism at the time of ET can increase pregnancy rates following IVF. The overall clinical and population PK data support future evaluation of higher doses and\/or alternate regimens of nolasiban in women undergoing ET following IVF.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>STUDY FUNDING\/COMPETING INTERESTS<\/jats:title>\n                  <jats:p>The trials were designed, conducted and funded by ObsEva SA. A.H., O.P., E.G., E.L. are employees and stockholders of ObsEva SA. E.L. is a board member of ObsEva SA. G.G. reports honoraria and\/or non-financial support from ObsEva, Merck, MSD, Ferring, Abbott, Gedeon-Richter, Theramex, Guerbet, Finox, Biosilu, Preglem and ReprodWissen GmbH. C.B. reports grants and honoraria from ObsEva, Ferring, Abbott, Gedeon Richter and MSD. P.P. reports consulting fees from ObsEva. H.T. reports grants and or fees from ObsEva, Research Fund of Flanders, Cook, MSD, Roche, Gedeon Richter, Abbott, Theramex and Ferring. H.V. reports grants from ObsEva and non-financial support from Ferring. P.T. is an employee of Cytel Inc., who provides statistical services to ObsEva. J.D. reports consulting fees and other payments from ObsEva and, Scientific Advisory Board membership of ObsEva.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>TRIAL REGISTRATION NUMBERS<\/jats:title>\n                  <jats:p>ClinicalTrials.gov: NCT02310802, NCT03081208, NCT03758885<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>TRIAL REGISTRATION DATES<\/jats:title>\n                  <jats:p>December 2014 (NCT02310802), March 2017 (NCT03081208), November 2018 (NCT03758885)<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>FIRST PATIENT\u2019s ENROLMENT<\/jats:title>\n                  <jats:p>January 2015 (NCT02310802), March 2017 (NCT03081208), November 2018 (NCT03758885).<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/humrep\/deaa369","type":"journal-article","created":{"date-parts":[[2020,12,28]],"date-time":"2020-12-28T20:13:48Z","timestamp":1609186428000},"page":"1007-1020","source":"Crossref","is-referenced-by-count":17,"title":["Effect of the oxytocin receptor antagonist nolasiban on pregnancy rates in women undergoing embryo transfer following IVF: analysis of three randomised clinical trials"],"prefix":"10.1093","volume":"36","author":[{"given":"G","family":"Griesinger","sequence":"first","affiliation":[{"name":"Department of Gynecological Endocrinology and Reproductive Medicine, University Hospital of Schleswig-Holstein, 23538 Kiel, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Blockeel","sequence":"additional","affiliation":[{"name":"Centre for Reproductive Medicine, Universitair Ziekenhuis, 1090 Brussel, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Pierzynski","sequence":"additional","affiliation":[{"name":"OVIklinika Warszawa Fertility Centre, 01-377 Warszawa, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":", H","family":"Tournaye","sequence":"additional","affiliation":[{"name":"Centre for Reproductive Medicine, Universitair Ziekenhuis, 1090 Brussel, Belgium"},{"name":"Department of Obstetrics, Gynecology, Perinatology and Reproduction, Institute of Professional Education, Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Trubetskaya str., 8, b. 2, 119992, Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Vi\u0161\u0148ov\u00e1","sequence":"additional","affiliation":[{"name":"IVF Cube, Prague 160 00, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Humberstone","sequence":"additional","affiliation":[{"name":"ObsEva Inc., Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Terrill","sequence":"additional","affiliation":[{"name":"Cytel Inc., Cambridge, MA 02139, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O","family":"Pohl","sequence":"additional","affiliation":[{"name":"ObsEva Inc., Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Garner","sequence":"additional","affiliation":[{"name":"ObsEva Inc., Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Donnez","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Catholique de Louvain, 1150, Brussels, Belgium"},{"name":"SRI (Soci\u00e9t\u00e9 de recherches pour l'infertilit\u00e9), 1150, Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Loumaye","sequence":"additional","affiliation":[{"name":"ObsEva Inc., Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,2,4]]},"reference":[{"key":"2021031813500401500_deaa369-B1","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1093\/humrep\/der037","article-title":"The Istanbul consensus workshop on embryo assessment: proceedings of an expert meeting","volume":"26","author":"Alpha Scientists in Reproductive Medicine and ESHRE Special Interest Group of Embryology","year":"2011","journal-title":"Hum Reprod"},{"key":"2021031813500401500_deaa369-B2","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0015-0282(97)81391-X","article-title":"Revised American Society for Reproductive Medicine classification of endometriosis: 1996","volume":"67","author":"American Society for Reproductive Medicine","year":"1997","journal-title":"Fertil Steril"},{"key":"2021031813500401500_deaa369-B3","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/humupd\/dmz001","article-title":"The health of children conceived by ART: 'the chicken or the egg?","volume":"25","author":"Berntsen","year":"2019","journal-title":"Hum Reprod Update"},{"key":"2021031813500401500_deaa369-B4","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.fertnstert.2014.03.047","article-title":"Ongoing pregnancy qualifies best as the primary outcome measure of choice in trials in reproductive medicine: an opinion paper","volume":"101","author":"Braakhekke","year":"2014","journal-title":"Fertil Steril"},{"key":"2021031813500401500_deaa369-B5","author":"CDC","year":"2016"},{"key":"2021031813500401500_deaa369-B6","first-page":"227","article-title":"The role of oxytocin antagonists in repeated implantation-failure","volume":"4","author":"Decleer","year":"2012","journal-title":"Facts Views Vis Obgyn"},{"key":"2021031813500401500_deaa369-B7","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1093\/humrep\/13.7.1968","article-title":"Uterine contractions at the time of embryo transfer alter pregnancy rates after in-vitro fertilization","volume":"13","author":"Fanchin","year":"1998","journal-title":"Hum Reprod"},{"key":"2021031813500401500_deaa369-B8","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/humupd\/dmu064","article-title":"Diagnosis of human preimplantation embryo viability","volume":"21","author":"Gardner","year":"2015","journal-title":"Hum Reprod Update"},{"key":"2021031813500401500_deaa369-B9","first-page":"CD002118","article-title":"Cleavage stage versus blastocyst stage embryo transfer in assisted reproductive technology","author":"Glujovsky","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2021031813500401500_deaa369-B10","doi-asserted-by":"crossref","first-page":"i6295","DOI":"10.1136\/bmj.i6295","article-title":"Lack of evidence for interventions offered in UK fertility centres","volume":"355","author":"Heneghan","year":"2016","journal-title":"BMJ"},{"key":"2021031813500401500_deaa369-B11","doi-asserted-by":"crossref","first-page":"e0175501","DOI":"10.1371\/journal.pone.0175501","article-title":"The impact of atosiban on pregnancy outcomes in women undergoing in vitro fertilization-embryo transfer: a meta-analysis","volume":"12","author":"Huang","year":"2017","journal-title":"PLoS One"},{"key":"2021031813500401500_deaa369-B12","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s00404-011-2019-2","article-title":"Three dimensional power Doppler evaluation of human endometrium after administration of oxytocine receptor antagonist (OTRa) in an IVF program","volume":"285","author":"Kalmantis","year":"2012","journal-title":"Arch Gynecol Obstet"},{"key":"2021031813500401500_deaa369-B13","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.tjog.2013.05.007","article-title":"Detection of endometrial and subendometrial vasculature on the day of embryo transfer and prediction of pregnancy during fresh in vitro fertilization cycles","volume":"53","author":"Kim","year":"2014","journal-title":"Taiwan J Obstet Gynecol"},{"key":"2021031813500401500_deaa369-B14","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1124\/mol.116.106013","article-title":"Differential effects of oxytocin receptor antagonists","volume":"91","author":"Kim","year":"2017","journal-title":"Mol Pharmacol"},{"key":"2021031813500401500_deaa369-B15","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.fertnstert.2019.10.011","article-title":"In vitro fertilization add-ons for the endometrium: it doesn\u2019t add-up","volume":"112","author":"Lensen","year":"2019","journal-title":"Fertil Steril"},{"key":"2021031813500401500_deaa369-B16","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1002\/sim.4289","article-title":"Subgroup identification based on differential effect search - a recursive partitioning method for establishing response to treatment in patient subpopulations","volume":"30","author":"Lipkovich","year":"2011","journal-title":"Statist Med"},{"key":"2021031813500401500_deaa369-B17","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1056\/NEJMoa1110238","article-title":"Cumulative birth rates with linked assisted reproductive technology cycles","volume":"366","author":"Luke","year":"2012","journal-title":"N Engl J Med"},{"key":"2021031813500401500_deaa369-B18","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1056\/NEJMe1815042","article-title":"Scratching the endometrium in in vitro fertilization\u2014time to stop","volume":"380","author":"Mol","year":"2019","journal-title":"N Engl J Med"},{"key":"2021031813500401500_deaa369-B19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.rbmo.2010.09.015","article-title":"Oxytocin and vasopressin V(1A) receptors as new therapeutic targets in assisted reproduction","volume":"22","author":"Pierzynski","year":"2011","journal-title":"Reprod Biomed Online"},{"key":"2021031813500401500_deaa369-B20","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.fertnstert.2006.09.017","article-title":"Oxytocin antagonists may improve infertility treatment","volume":"88","author":"Pierzynski","year":"2007","journal-title":"Fertil Steril"},{"key":"2021031813500401500_deaa369-B21","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.rbmo.2019.06.002","article-title":"Oxytocin antagonism reverses the effects of high oestrogen levels and oxytocin on decidualization and cyclooxygenase activity in endometrial tissues","volume":"39","author":"Sztachelska","year":"2019","journal-title":"Reprod Biomed Online"},{"key":"2021031813500401500_deaa369-B22","first-page":"556","article-title":"Cumulative live-birth rates after one ART cycle including all subsequent frozen-thaw cycles in 1050 women: secondary outcome of an RCT comparing GnRH-antagonist and GnRH-agonist protocols","volume":"32","author":"Toftager","year":"2017","journal-title":"Hum Reprod"},{"key":"2021031813500401500_deaa369-B23","first-page":"i12","article-title":"A placebo-controlled, randomized, double-blind study of pregnancy and live birth rates after single oral administration of a novel oxytocin antagonist, nolasiban, prior to embryo transfer","volume":"32","author":"Tournaye","year":"2017","journal-title":"Hum Reprod"},{"key":"2021031813500401500_deaa369-B24","article-title":"Luteal phase support for assisted reproduction cycles","volume":"2015","author":"van der Linden","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2021031813500401500_deaa369-B25","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1093\/humrep\/deu058","article-title":"Uterine peristalsis before embryo transfer affects the chance of clinical pregnancy in fresh and frozen-thawed embryo transfer cycles","volume":"29","author":"Zhu","year":"2014","journal-title":"Hum Reprod"}],"container-title":["Human Reproduction"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/humrep\/article-pdf\/36\/4\/1007\/36638028\/deaa369.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/humrep\/article-pdf\/36\/4\/1007\/36638028\/deaa369.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T13:51:23Z","timestamp":1616075483000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/humrep\/article\/36\/4\/1007\/6127349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,4]]},"references-count":25,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,2,4]]},"published-print":{"date-parts":[[2021,3,18]]}},"URL":"https:\/\/doi.org\/10.1093\/humrep\/deaa369","relation":{},"ISSN":["0268-1161","1460-2350"],"issn-type":[{"value":"0268-1161","type":"print"},{"value":"1460-2350","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,4,1]]},"published":{"date-parts":[[2021,2,4]]}}}